Mouse Model of In Situ Thromboembolic Stroke and Reperfusion

• DOI: 10.1161/strokeaha.107.487520
• Publication Date: 2007-08-17T00:54:47Z
• Authors: Cyrille Orset; Richard Macrez; Alan R. Young; Didier Panthou; Eduardo Angles-Cano; Eric Maubert; Veronique Agin; Denis Vivien
• Keywords: Stroke; Thromboembolic stroke; T-plasminogen activator

Early reperfusion using tissue-type plasminogen activator is the only therapeutic agent to treat focal cerebral ischemia with proven efficacy in patients. Nevertheless, novel insights into pathophysiology of neurons, glial cells, and fate endothelium after stroke call for use new strategies improve treatment alone or combination activator-induced thrombolysis. Unfortunately, despite plethora drugs that display clear beneficial effects animal models experimental ischemia, their subsequent clinical trials has disappointing. As such, one forced consider may be required before evaluation a molecule.In situ microinjection purified murine thrombin was used trigger local clot formation anesthetized mice. Cerebral blood velocity measured continuously throughout duration study. The efficiency recombinant induce thrombolysis its effect on infarct volume were then measured.In injection leads reproducible cortical brain injury. Recombinant reduced by 36.8% when compared untreated control mice.We describe an original mouse model reperfusion, which could investigate treatment.